Vaishali Pharma Limited (VAISHALI.NS)

Vaishali Pharma Limited functions as a pharmaceutical enterprise, conducting its business both within India and across global markets. The company's extensive product portfolio encompasses Active Pharmaceutical Ingredients (APIs), covering a broad spectrum of therapeutic areas. These include substances used in the treatment of bacterial infections (antibiotics), digestive issues (anti-ulcer), pain and inflammation (anti-inflammatory, analgesic, antipyretic), malaria, cardiovascular conditions, diabetes, common cold and allergies, diarrheal and parasitic diseases, viral infections, epilepsy, asthma, fungal infections, blood clot prevention (anti-platelet agents), muscle relaxation, and parasitic worm infections (anti-helmintics). Beyond these, Vaishali Pharma also supplies excipients, topical steroids, corticosteroids, and various enzymes. In addition to APIs, the company manufactures and distributes a diverse range of finished pharmaceutical formulations. These include prepared medications for bacterial infections, anti-platelet actions, laxative effects, digestive/enzyme support, asthma, malaria, cold/allergy/viral symptoms, psychotic disorders, fungal infections, pain/inflammation, diabetes, cardiac ailments, vitamin deficiencies, and topical steroid/corticosteroid applications, among other general formulations. Furthermore, its offerings extend to specialized segments such as veterinary pharmaceuticals, nutraceuticals, oncology products, herbal remedies, and surgical supplies. Established in 1989, the company maintains its corporate headquarters in Mumbai, India.

No mergers or acquisitions recorded for this company.